Clinical Trial Detail

NCT ID NCT03613532
Title Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Jacqueline Garcia, MD
Indications

acute myeloid leukemia

myelodysplastic syndrome

chronic myelomonocytic leukemia

myelodysplastic/myeloproliferative neoplasm

Therapies

Busulfan + Fludarabine + Venetoclax

Age Groups: adult senior

Additional content available in CKB BOOST